Reported
Nanexa Shares Surge Over 150% After Licensing Deal With Novo Nordisk
The Swedish drug-delivery microcap's stock more than doubled following a licensing agreement with the maker of Wegovy.
· 1 min read
Novo Nordisk
Reported
Novo Nordisk's new strategy depends on rebuilding investor trust, CEO says
CEO Mike Doustdar says Novo Nordisk is ready to broaden its ambitions again, but investors remain unconvinced after a period of setbacks for the drugmaker.
· 1 min read
EGEGazette
Reported
Novo Nordisk shares fall as company outlines strategy beyond Wegovy
The Danish drugmaker is seeking to reassure investors it can compete in the increasingly crowded weight-loss drug market, CNBC reported.
· 1 min read
EGEGazette
Reported
Novo Nordisk shares drop as much as 7% despite $23 billion obesity drug sales target
The decline came even as the Danish drugmaker set an ambitious sales goal for its weight-loss treatments, CNBC reported.
· 1 min read
EGEGazette
Reported
Novo Nordisk Rebrands to 'Novo,' CEO Says Obesity Strategy Needs Rethink
In an interview with CNBC, new chief executive Mike Doustdar said the Danish drugmaker's rebranding marks a new chapter as it faces intensifying competition from Eli Lilly.
· 1 min read